CN101056974A - 鉴定和分离来自非骨软骨间充质组织的多潜能细胞 - Google Patents
鉴定和分离来自非骨软骨间充质组织的多潜能细胞 Download PDFInfo
- Publication number
- CN101056974A CN101056974A CNA2005800390995A CN200580039099A CN101056974A CN 101056974 A CN101056974 A CN 101056974A CN A2005800390995 A CNA2005800390995 A CN A2005800390995A CN 200580039099 A CN200580039099 A CN 200580039099A CN 101056974 A CN101056974 A CN 101056974A
- Authority
- CN
- China
- Prior art keywords
- cell
- multipotent adult
- present
- tissue
- arbitrary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissue Anatomy 0.000 title claims description 69
- 210000000988 bone and bone Anatomy 0.000 title claims description 52
- 210000000845 cartilage Anatomy 0.000 title claims description 41
- 210000004027 cell Anatomy 0.000 claims abstract description 497
- -1 CD49A Proteins 0.000 claims abstract description 15
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 14
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 14
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims abstract description 12
- 102100022749 Aminopeptidase N Human genes 0.000 claims abstract description 12
- 102100022002 CD59 glycoprotein Human genes 0.000 claims abstract description 12
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims abstract description 12
- 102100037241 Endoglin Human genes 0.000 claims abstract description 12
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims abstract description 12
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims abstract description 12
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims abstract description 12
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims abstract description 12
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims abstract description 12
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims abstract description 12
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims abstract description 12
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims abstract description 12
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 claims abstract description 12
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims abstract description 12
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims abstract description 12
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 12
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 12
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims abstract description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 12
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims abstract description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 12
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims abstract description 12
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims abstract description 12
- 102100032816 Integrin alpha-6 Human genes 0.000 claims abstract description 12
- 102100022337 Integrin alpha-V Human genes 0.000 claims abstract description 12
- 102100025304 Integrin beta-1 Human genes 0.000 claims abstract description 12
- 102100033000 Integrin beta-4 Human genes 0.000 claims abstract description 12
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims abstract description 12
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims abstract description 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract description 12
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims abstract description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 12
- 102000003729 Neprilysin Human genes 0.000 claims abstract description 12
- 108090000028 Neprilysin Proteins 0.000 claims abstract description 12
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract description 12
- 102100040120 Prominin-1 Human genes 0.000 claims abstract description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 12
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims abstract description 12
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims abstract description 12
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract description 11
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 102100037904 CD9 antigen Human genes 0.000 claims abstract description 10
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 76
- 238000000926 separation method Methods 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 33
- 235000015097 nutrients Nutrition 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000011069 regeneration method Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 238000001228 spectrum Methods 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 12
- 230000017423 tissue regeneration Effects 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 239000006285 cell suspension Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 8
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 7
- 238000001976 enzyme digestion Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000001612 chondrocyte Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000003725 endotheliocyte Anatomy 0.000 claims description 4
- 210000000107 myocyte Anatomy 0.000 claims description 4
- 210000001130 astrocyte Anatomy 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 210000004248 oligodendroglia Anatomy 0.000 claims description 3
- 210000004409 osteocyte Anatomy 0.000 claims description 3
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- 238000002955 isolation Methods 0.000 abstract description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 abstract 3
- 239000000243 solution Substances 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 20
- 239000007788 liquid Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000004504 adult stem cell Anatomy 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000007443 liposuction Methods 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 239000002458 cell surface marker Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012447 hatching Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 230000024835 cytogamy Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100029563 Somatostatin Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002642 osteogeneic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200402355A ES2313805B1 (es) | 2004-10-04 | 2004-10-04 | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
ES200402355 | 2004-10-04 | ||
PCT/EP2005/010811 WO2006037649A1 (en) | 2004-10-04 | 2005-10-04 | Identification and insolation of multipotent cells from non-osteochondral mesenchymal tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101056974A true CN101056974A (zh) | 2007-10-17 |
CN101056974B CN101056974B (zh) | 2015-11-25 |
Family
ID=35457282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200580039099.5A Active CN101056974B (zh) | 2004-10-04 | 2005-10-04 | 鉴定和分离来自非骨软骨间充质组织的多潜能细胞 |
Country Status (17)
Country | Link |
---|---|
US (3) | US20060073124A1 (zh) |
EP (5) | EP2292736B1 (zh) |
JP (2) | JP2008515413A (zh) |
KR (1) | KR20070085294A (zh) |
CN (1) | CN101056974B (zh) |
AU (1) | AU2005291353A1 (zh) |
CA (1) | CA2583151C (zh) |
CY (1) | CY1116198T1 (zh) |
DK (1) | DK2292736T3 (zh) |
ES (2) | ES2313805B1 (zh) |
HU (1) | HUE025155T2 (zh) |
IL (1) | IL182441A (zh) |
PL (1) | PL2292736T3 (zh) |
PT (1) | PT2292736E (zh) |
SG (2) | SG158853A1 (zh) |
SI (1) | SI2292736T1 (zh) |
WO (1) | WO2006037649A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102257388A (zh) * | 2008-08-18 | 2011-11-23 | 成血管细胞系统公司 | 单克隆抗体stro-4 |
CN103289955A (zh) * | 2012-03-01 | 2013-09-11 | 美天旎生物技术有限公司 | 未触及的活神经元的分离 |
CN108883135A (zh) * | 2016-03-14 | 2018-11-23 | 泰根尼克斯独资有限公司 | 用于治疗克罗恩病的难治性、复杂性肛周瘘的脂肪组织来源的基质干细胞 |
CN109863399A (zh) * | 2016-08-26 | 2019-06-07 | 朱诺治疗学股份有限公司 | 计数存在于细胞组合物中的颗粒的方法 |
CN110090300A (zh) * | 2018-01-29 | 2019-08-06 | 中国科学院动物研究所 | 一种促进组织器官的再生修复的方法及其应用 |
CN114540285A (zh) * | 2017-06-25 | 2022-05-27 | 科.东股份公司 | 用于制备可移植性软骨组织的方法 |
US11622964B2 (en) | 2018-01-29 | 2023-04-11 | Institute Of Zoology, Chinese Academy Of Sciences | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807458B2 (en) | 2003-01-30 | 2010-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs | Multilineage-inducible cells and uses thereof |
CN100377165C (zh) * | 2003-04-24 | 2008-03-26 | 皇家飞利浦电子股份有限公司 | 无创式左心室的容积测定 |
US7266519B2 (en) * | 2003-06-30 | 2007-09-04 | Qualcomm Incorporated | Billing system with authenticated wireless device transaction event data |
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
ES2313805B1 (es) | 2004-10-04 | 2009-12-23 | Cellerix, S.L. | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
AU2005304708B2 (en) * | 2004-11-08 | 2012-01-19 | The Johns Hopkins University | Cardiac stem cells |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
EP3184630B1 (en) | 2005-09-23 | 2019-07-17 | TiGenix, S.A.U. | Cell populations having immunoregulatory activity, method for isolation and uses |
WO2007087519A2 (en) * | 2006-01-24 | 2007-08-02 | Centeno Christopher J | Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting |
US20080025953A1 (en) * | 2006-07-25 | 2008-01-31 | Kiminobu Sugaya | Vigor Enhancement of Animals Via Administration of Stem Cells |
KR100827660B1 (ko) | 2006-10-25 | 2008-05-07 | 대한민국 (식품의약품안전청장) | Cd9를 발현하는 인간 중간엽 줄기세포의 선별 및배양방법 |
CA2913024A1 (en) * | 2006-11-03 | 2008-05-08 | Aastrom Biosciences, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
KR101240487B1 (ko) * | 2006-11-09 | 2013-03-08 | 더 존스 홉킨스 유니버시티 | 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화 |
FR2918073B1 (fr) * | 2007-06-27 | 2012-10-19 | Univ Paris Curie | Cellules fixatrices de cellules tumorales. |
US9095562B2 (en) * | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
CN101945994A (zh) | 2007-12-19 | 2011-01-12 | 再生科学有限责任公司 | 促进干细胞移植和植入的组合物和方法 |
CN102026546A (zh) | 2008-03-14 | 2011-04-20 | 再生科学有限责任公司 | 软骨修复的合成物和方法 |
GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
AU2015268704B2 (en) * | 2008-08-04 | 2017-08-10 | Consejo Superior De Investigaciones Cientificas | Uses of mesenchymal stem cells |
WO2010065854A1 (en) | 2008-12-05 | 2010-06-10 | Regenerative Sciences, Llc | Methods and compositions to facilitate repair of avascular tissue |
US20100168022A1 (en) * | 2008-12-11 | 2010-07-01 | Centeno Christopher J | Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens |
US20110054929A1 (en) * | 2009-09-01 | 2011-03-03 | Cell Solutions Colorado Llc | Stem Cell Marketplace |
JP5810435B2 (ja) * | 2009-09-30 | 2015-11-11 | 国立大学法人 熊本大学 | 内胚葉細胞、腸管細胞又は膵細胞の検出方法 |
US9113950B2 (en) | 2009-11-04 | 2015-08-25 | Regenerative Sciences, Llc | Therapeutic delivery device |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
AU2012275335B2 (en) | 2011-06-29 | 2017-04-20 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
JP2015521054A (ja) | 2012-06-05 | 2015-07-27 | カプリコール,インコーポレイテッド | 心臓組織から心臓幹細胞を作製するための最適化方法および心臓治療におけるそれらの使用 |
JP6433896B2 (ja) | 2012-08-13 | 2018-12-05 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
JP6887249B2 (ja) | 2013-04-19 | 2021-06-16 | バイオリストーラティブ セラピーズ, インコーポレイテッド | ヒト褐色脂肪由来幹細胞およびその使用 |
MX2016001247A (es) | 2013-07-30 | 2016-08-17 | Musculoskeletal Transplant Foundation | Matrices derivadas de tejido suave acelular y metodos para preparar las mismas. |
BR102013033827B1 (pt) * | 2013-12-27 | 2021-09-08 | Regenera - Medicina Veterinária Avançada Ltda. | Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem |
WO2016054591A1 (en) | 2014-10-03 | 2016-04-07 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
EP3381458B1 (en) | 2015-11-24 | 2023-06-07 | Rohto Pharmaceutical Co., Ltd. | Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same |
JP6714932B2 (ja) * | 2015-12-01 | 2020-07-01 | 株式会社AdipoSeeds | 脊椎動物の脂肪組織由来間葉系細胞株の製造方法 |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2018255346B2 (en) | 2017-04-19 | 2024-05-02 | Capricor, Inc. | Methods and compositions for treating skeletal muscular dystrophy |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
ES2957507A1 (es) * | 2022-06-09 | 2024-01-19 | Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz | Tratamiento de la disfuncion de las glandulas de meibomio |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US6294346B1 (en) | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
CA2253724A1 (en) | 1996-04-26 | 1997-11-06 | Case Western Reserve University | Skin regeneration using mesenchymal stem cells |
AU9127098A (en) | 1997-09-04 | 1999-03-22 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
WO1999047163A2 (en) | 1998-03-18 | 1999-09-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
KR100968164B1 (ko) * | 1999-03-10 | 2010-07-06 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 지방 유래 간세포 및 격자 |
US20030082152A1 (en) * | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
US20050153442A1 (en) * | 1999-03-10 | 2005-07-14 | Adam Katz | Adipose-derived stem cells and lattices |
US7670628B2 (en) * | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
AU3869501A (en) * | 2000-02-26 | 2001-09-03 | Artecel Sciences Inc | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
CA2489212C (en) * | 2002-06-14 | 2012-08-14 | Cartela Ab | Marker for stem cells and its use |
WO2004013275A2 (fr) * | 2002-07-31 | 2004-02-12 | Yves Saint-Laurent Parfums | Cellules souches issues de tissu adipeux et cellules differenciees issues de ces cellules |
ES2265199B1 (es) * | 2003-06-12 | 2008-02-01 | Cellerix, S.L. | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
US9074190B2 (en) * | 2003-10-07 | 2015-07-07 | Biomaster, Inc. | Cell differentiation of adipose-derived precursor cells |
ATE493492T1 (de) * | 2003-11-04 | 2011-01-15 | Biomaster Inc | Verfahren und system zur herstellung von stammzellen aus fettgewebe |
EP2298862B1 (en) | 2004-03-22 | 2017-08-30 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
RU2252252C1 (ru) * | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Способ выделения мезенхимальных стволовых клеток |
ES2313805B1 (es) | 2004-10-04 | 2009-12-23 | Cellerix, S.L. | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
ES2264862B8 (es) | 2004-08-25 | 2017-01-20 | Cellerix, S.L. | Biomaterial para sutura. |
GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
-
2004
- 2004-10-04 ES ES200402355A patent/ES2313805B1/es active Active
-
2005
- 2005-02-25 US US11/065,461 patent/US20060073124A1/en not_active Abandoned
- 2005-10-04 WO PCT/EP2005/010811 patent/WO2006037649A1/en active Application Filing
- 2005-10-04 SG SG201000029-7A patent/SG158853A1/en unknown
- 2005-10-04 ES ES10183073.5T patent/ES2535042T3/es active Active
- 2005-10-04 PT PT101830735T patent/PT2292736E/pt unknown
- 2005-10-04 HU HUE10183073A patent/HUE025155T2/en unknown
- 2005-10-04 CN CN200580039099.5A patent/CN101056974B/zh active Active
- 2005-10-04 EP EP10183073.5A patent/EP2292736B1/en not_active Revoked
- 2005-10-04 KR KR1020077010158A patent/KR20070085294A/ko not_active Application Discontinuation
- 2005-10-04 US US11/576,573 patent/US20070248580A1/en not_active Abandoned
- 2005-10-04 SI SI200531957T patent/SI2292736T1/sl unknown
- 2005-10-04 EP EP18152520.5A patent/EP3342857A1/en not_active Ceased
- 2005-10-04 CA CA2583151A patent/CA2583151C/en active Active
- 2005-10-04 AU AU2005291353A patent/AU2005291353A1/en not_active Abandoned
- 2005-10-04 JP JP2007535099A patent/JP2008515413A/ja not_active Withdrawn
- 2005-10-04 PL PL10183073T patent/PL2292736T3/pl unknown
- 2005-10-04 EP EP05796904A patent/EP1812558A1/en not_active Withdrawn
- 2005-10-04 EP EP20140196588 patent/EP2862925A1/en not_active Withdrawn
- 2005-10-04 SG SG2013051040A patent/SG192459A1/en unknown
- 2005-10-04 DK DK10183073.5T patent/DK2292736T3/en active
- 2005-10-04 EP EP16206687.2A patent/EP3165601A1/en not_active Withdrawn
-
2007
- 2007-04-10 IL IL182441A patent/IL182441A/en active IP Right Grant
-
2012
- 2012-08-24 JP JP2012185671A patent/JP5732011B2/ja active Active
-
2015
- 2015-04-17 CY CY20151100356T patent/CY1116198T1/el unknown
- 2015-08-24 US US14/834,006 patent/US10729726B2/en active Active
Non-Patent Citations (5)
Title |
---|
DE UGARTE DA等: "Comparison of multi-lineage cells from human adipose tissue and bone marrow", 《CELLS TISSUES ORGANS.》 * |
HATTORI H等: "Osteogenic potential of human adipose tissue-derived stromal cells as an alternative stem cell source", 《CELLS TISSUES ORGANS.》 * |
LEE RH等: "Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue", 《CELL PHYSIOL BIOCHEM.》 * |
ZUK PA等: "Human adipose tissue is a source of multipotent stem cells", 《MOL BIOL CELL.》 * |
ZUK PA等: "Multilineage cells from human adipose tissue: implications for cell-based therapies", 《TISSUE ENG.》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102257388A (zh) * | 2008-08-18 | 2011-11-23 | 成血管细胞系统公司 | 单克隆抗体stro-4 |
CN102257388B (zh) * | 2008-08-18 | 2015-03-18 | 中胚有限公司 | 单克隆抗体stro-4 |
CN104678106A (zh) * | 2008-08-18 | 2015-06-03 | 中胚有限公司 | 单克隆抗体stro-4 |
CN103289955A (zh) * | 2012-03-01 | 2013-09-11 | 美天旎生物技术有限公司 | 未触及的活神经元的分离 |
CN108883135A (zh) * | 2016-03-14 | 2018-11-23 | 泰根尼克斯独资有限公司 | 用于治疗克罗恩病的难治性、复杂性肛周瘘的脂肪组织来源的基质干细胞 |
CN108883135B (zh) * | 2016-03-14 | 2022-11-04 | 武田药品工业株式会社 | 用于治疗克罗恩病的难治性、复杂性肛周瘘的脂肪组织来源的基质干细胞 |
CN109863399A (zh) * | 2016-08-26 | 2019-06-07 | 朱诺治疗学股份有限公司 | 计数存在于细胞组合物中的颗粒的方法 |
CN114540285A (zh) * | 2017-06-25 | 2022-05-27 | 科.东股份公司 | 用于制备可移植性软骨组织的方法 |
CN110090300A (zh) * | 2018-01-29 | 2019-08-06 | 中国科学院动物研究所 | 一种促进组织器官的再生修复的方法及其应用 |
US11622964B2 (en) | 2018-01-29 | 2023-04-11 | Institute Of Zoology, Chinese Academy Of Sciences | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
SG192459A1 (en) | 2013-08-30 |
ES2313805B1 (es) | 2009-12-23 |
AU2005291353A1 (en) | 2006-04-13 |
US10729726B2 (en) | 2020-08-04 |
CY1116198T1 (el) | 2017-02-08 |
WO2006037649A1 (en) | 2006-04-13 |
JP5732011B2 (ja) | 2015-06-10 |
US20170296585A1 (en) | 2017-10-19 |
EP2292736A2 (en) | 2011-03-09 |
PT2292736E (pt) | 2015-04-29 |
EP3342857A1 (en) | 2018-07-04 |
SI2292736T1 (sl) | 2015-05-29 |
JP2008515413A (ja) | 2008-05-15 |
ES2535042T3 (es) | 2015-05-04 |
CA2583151A1 (en) | 2006-04-13 |
EP2862925A1 (en) | 2015-04-22 |
US20060073124A1 (en) | 2006-04-06 |
EP1812558A1 (en) | 2007-08-01 |
EP3165601A1 (en) | 2017-05-10 |
IL182441A (en) | 2015-08-31 |
DK2292736T3 (en) | 2015-04-20 |
ES2313805A1 (es) | 2009-03-01 |
SG158853A1 (en) | 2010-02-26 |
KR20070085294A (ko) | 2007-08-27 |
HUE025155T2 (en) | 2016-03-29 |
PL2292736T3 (pl) | 2015-07-31 |
CA2583151C (en) | 2015-09-15 |
JP2013013411A (ja) | 2013-01-24 |
EP2292736A3 (en) | 2011-06-15 |
EP2292736B1 (en) | 2015-01-21 |
IL182441A0 (en) | 2007-07-24 |
CN101056974B (zh) | 2015-11-25 |
US20070248580A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101056974A (zh) | 鉴定和分离来自非骨软骨间充质组织的多潜能细胞 | |
CN104204193B (zh) | 间充质干细胞的培养 | |
CN1281739C (zh) | 从脐带血中分离并扩大培养间充质干细胞/祖细胞及将脐带血来源的间充质干细胞/祖细胞分化成各种间充质组织的方法 | |
US20070243172A1 (en) | Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same | |
JP5155855B2 (ja) | 多分化性幹細胞の単離 | |
CN1452655A (zh) | 间充质类干细胞的培养方法 | |
CN1636054A (zh) | 来自人胚胎干细胞的间充质细胞和成骨细胞 | |
EP3578641A1 (en) | Method for preparing dental pulp stem cells from cells derived from dental pulp tissue | |
CN106282108A (zh) | 一种具有免疫调节功能的脾脏间充质干细胞及其制备方法与应用 | |
CN101052711A (zh) | 制备星形胶质细胞样细胞的条件培养基的方法 | |
Croft et al. | Mesenchymal stem cells from the bone marrow stroma: basic biology and potential for cell therapy | |
US20080299656A1 (en) | Isolation of multi-lineage stem cells | |
Kadivar et al. | Isolation, culture and characterization of postnatal human umbilical vein-derived mesenchymal stem cells | |
AU2011253985C1 (en) | Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue | |
Grimm et al. | Isolation of skeletal muscle-derived cells modeling Neural Crest-derived Stem Cells for Therapeutic Use in Regenerative Periodontology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Madrid Patentee after: TIGENIX N.V. Patentee after: UNIVERSIDAD AUTONOMA DE MADRID Address before: Madrid Patentee before: CELLERIX, S.L. Patentee before: UNIVERSIDAD AUTONOMA DE MADRID |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221104 Address after: Osaka, Japan Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd. Patentee after: UNIVERSIDAD AUTONOMA DE MADRID Address before: Madrid Patentee before: TIGENIX N.V. Patentee before: UNIVERSIDAD AUTONOMA DE MADRID |
|
TR01 | Transfer of patent right |